Understanding biomarkers in metastatic colorectal cancer treatment
On-treatment Biomarkers in Metastatic Colorectal Cancer for Life: The On-CALL Study
Region Skane · NCT05755672
This study is trying to see how cancer changes during treatment in people with metastatic colorectal cancer and whether certain genetic markers can help tailor better treatment options for them.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 100 (estimated) |
| Ages | 18 Years to 110 Years |
| Sex | All |
| Sponsor | Region Skane (other) |
| Locations | 2 sites (Lund, Skåne County and 1 other locations) |
| Trial ID | NCT05755672 on ClinicalTrials.gov |
What this trial studies
The On-treatment biomarkers in metastatic ColorectAL cancer for Life (On-CALL) study aims to explore the evolutionary progression of metastatic colorectal cancer (mCRC) during treatment. This prospective observational study will analyze genetic heterogeneity across different metastatic sites and assess the role of circulating tumor DNA (ctDNA) as a biomarker for treatment response. By examining the tumor microenvironment and immune cell interactions, the study seeks to uncover mechanisms behind therapeutic failures in mCRC patients. The findings could lead to more personalized treatment strategies for patients undergoing chemotherapy and surgical interventions.
Who should consider this trial
Good fit: Ideal candidates for this study are patients diagnosed with synchronous metastatic colorectal cancer who are planning to undergo treatment with curative intent.
Not a fit: Patients who do not meet the inclusion criteria or are not willing to provide informed consent may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could enhance personalized treatment approaches for patients with metastatic colorectal cancer, potentially improving survival outcomes.
How similar studies have performed: Other studies have shown promise in understanding tumor heterogeneity and biomarkers in cancer treatment, suggesting that this approach could yield valuable insights.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Clinical diagnosis of synchronous metastatic colorectal cancer, planned cancer treatment with curative intent at the Skåne University Hospital Exclusion Criteria: * Not accepting the study inclusion terms (informed consent not obtained) * Age below or above the age limit
Where this trial is running
Lund, Skåne County and 1 other locations
- Department of Oncology, Hematology and Radiophysics, Skane University Hospital — Lund, Skåne County, Sweden (RECRUITING)
- Department of Oncology, Hematology and Radiophysics, Skane University Hospital — Malmö, Skåne County, Sweden (RECRUITING)
Study contacts
- Study coordinator: Danyil Kuznyecov, M.D.
- Email: danyil_szergejevics.kuznyecov@med.lu.se
- Phone: +46 725972072
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Metastatic Colorectal Cancer, Chemotherapy Effect, Peritoneal Metastases, Liver Metastasis Colon Cancer, Lung Metastases, Metastatic colorectal cancer, Chemotherapy, Targeted therapy